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Abstract
The precise mechanisms of kidney stone formation and growth are not completely known, even 
though human stone disease appears to be one of the oldest diseases known to medicine. With the 
advent of the new digital endoscope and detailed renal physiological studies performed on well 
phenotyped stone formers, substantial advances have been made in our knowledge of the 
pathogenesis of the most common type of stone former, the idiopathic calcium oxalate stone 
former (ICSF) as well as nine other stone forming groups. The observations from our group on 
human stone formers and those of others on model systems have suggested four entirely different 
pathways for kidney stone formation. Calcium oxalate stone growth over sites of Randall’s plaque 
appear to be the primary mode of stone formation for those patients with hypercalciuria. 
Overgrowths off the ends of Bellini duct plugs have been noted in most stone phenotypes, do they 
result in a clinical stone? Micro-lith formation does occur within the lumens of dilated inner 
medullary collecting ducts of cystinuric stone formers and appear to be confined to this space. 
Lastly, cystinuric stone formers also have numerous small, oval, smooth yellow appearing 
calyceal stones suggestive of formation in free solution. The scientific basis for each of these four 
modes of stone formation are reviewed and used to explore novel research opportunities.
Introduction
As the details of human stone formation have accumulated, new opportunities are arising for 
laboratory and clinical experiments, and our purpose here is to offer a review of details that 
appear crucial to human stone formation and also amenable to modern research techniques. 
Thus far we and others (1–22) have identified 4 different possible modes of stone formation: 
growth over white (Randall’s) interstitial hydroxyapatite (HA) plaque (1,2,4,6–9,12–
15,17,22); growth over Bellini duct (BD) plugs (3,5–11,13–16,18–22); formation of micro-
liths within inner medullary collecting ducts (IMCD) (3); and formation in free solution 
within the calyces or renal collecting system (3,18–21). Model systems, the usual 
conveyance from the clinic to the bench, have more or less benefitted nephrolithiasis 
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research, from animal models to in vitro studies of crystallization kinetics and inhibitors. 
Now that the details of human stone formation are becoming clear such models can be made 
to more closely resemble clinical reality.
Growth on plaque
Simple observation during the course of surgery for stone removal shows that stones can 
grow attached to plaque (Figure 1, panel a). Randall (22) in 1937 showed in cadavers more 
or less what modern surgeons easily visualize with digital optic scopes. When the stone is 
removed (Figure 1 panel b) the attachment site is often visible, as here, and is composed of 
HA. With effort one can reconstruct from intra-operative images (12) the exact location on 
plaque from which stones have been removed, and also prove that a majority of stones 
within a particular patient do indeed grow attached to papillae and specifically to the plaque 
regions of the papillae (12). In a similar vein, unattached stones can be recognized as having 
a plaque origin from their telltale HA attachment site residues (23).
With care, from the mass of stone formers, one can define what appears to be a reasonably 
pure phenotype: patients who form calcium oxalate (CaOx) stones and have no systemic 
disease as a cause of stones, who are named through long custom (24) ‘idiopathic’ CaOx 
stone formers (ICSF) (25). Many but not all of these ICSF have idiopathic hypercalciuria 
(IH) a familial and presumably genetic trait. ICSF form most of their CaOx stones on plaque 
as we have illustrated in Figure 1.
The earliest formation of RP appears to be in the basement membranes of the thin loops of 
Henle (Figure 2 panel a) as micro-spherulites made of alternating lamina of matrix with and 
without HA crystals (Figure 2 panels b–e) (1). As well, plaque particles nucleate in the 
interstitium, where instead of remaining separate as in the basement membranes they fuse to 
form a continuous pool of matrix in which HA crystals reside in isolated clumps (Figure 2 
panel f). It is the second form of plaque that extends between the tubules and vessels until it 
abuts against the limiting papillary epithelium (Figure 2 panel g). It is this plaque surgeons 
see as ‘white plaque’.
Given some breach of urothelial integrity, this plaque becomes exposed to urine (26). What 
is exposed is not HA crystals but the matrix in which they reside. The details of overgrowth 
can be visualized in small stones harvested with their tissue base (Figure 3, panels a and b) 
(27). The plaque area of overgrowth and the stone itself when restored to their original 
orientation with respect to one another (Figure 3 panel c) demonstrate epithelial disruption 
and separation of some plaque from tissue which is adherent to the base of the stone. 
Visualized by TEM (Figure 3 panel d) the plaque at the lower right of the panel shows white 
islands of HA within plaque matrix. The exposed plaque is covered by a ribbon of 
alternating matrix and HA crystals. The innermost layer of matrix (inset at upper right of 
panel) contains THP meaning that the matrix of exposed plaque is initially covered by an 
organic matrix of urine origin (27) as the interstitial matrix cannot normally have access to 
THP (28). As if to recapitulate the plaque particles, the HA crystals nucleate in alternating 
matrix layers, some layers free of crystals, some with crystals. At the terminal urinary 
border, crystals sweep into what was once the urinary space to form the base of the stone.
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The range of novel research opportunities offered by growth on plaque mirror our ignorance 
of the process. The earliest nuclei of plaque appear in the type 3 collagen of the thin limb 
basement membrane (Figure 4, left most cartoon). Why there? The driving forces can arise 
from the lumen or interstitial fluid. We (29) have gathered evidence that in animals thin limb 
fluid is supersaturated with respect to calcium phosphate (CaP) as brushite (BR). The ionic 
composition of the human interstitium is unknown. The epithelium of the thin limbs is very 
impermeable to calcium (30) but high fluid CaP SS may be present much of the day because 
IH, which involves increased calcium delivery out of the proximal tubule (31,32), manifests 
especially with meals (31–35).
Biophysical modelling using known permeabilities and ranges of reasonable interstitial 
molarities could perhaps help establish a range of SS for basement membrane. Likewise the 
composition of the membranes may be important. Why do the particles remain separate in 
the membrane? Why are they laminated? The nature of the particle matrix is not known 
except for osteopontin and the third heavy chain of the inter alpha trypsin inhibitor (36,37), 
nor why particles do not grow past a general size of 10 microns. Whether particles form 
directly on the basement membrane type 3 collagen, and if so where on the molecule, is also 
an open question. Do thin limb cells respond to the presence of the particles in the basement 
membrane via expression of novel proteins? Given proper techniques small samples from 
early plaque could help resolve these questions and open up the problem of membrane 
plaque genesis.
Interstitial plaque genesis (Figure 4, second cartoon, upper row) seems to be on type 1 
collagen (1,38), but the exact region of the collagen remains to be shown (1,38). The driving 
forces for crystallization are entirely interstitial and unknown in quantity. As for all plaque 
particles, radial layering remains a puzzle. Unlike in membranes, particles fuse; why this 
happens is unknown.
Nucleation of HA on types 1 and 3 collagen, if thoughtfully performed, might clarify what 
happens in human kidneys. More directly, samples from kidneys could be studied in terms 
of nucleation sites and mechanisms of fusion. As in the membrane the matrix molecules are 
poorly described. We have described only osteopontin and the third heavy chain of the inter-
alpha trypsin inhibitor (36,37). This latter is known to stabilize collagen structures after 
injury (39); is its presence evidence of injury from plaque that we cannot recognize, or is it 
remodeling?
What controls interstitial calcium concentration is unknown for papillum. We (13) have 
proposed vas washdown, the down transport in vasa recta of calcium reabsorbed in outer 
medullary thick ascending limbs which is available to pre-load descending vessels as they 
traverse the outer medulla in the vascular bundles. Increased proximal tubule delivery of 
calcium occurs in some IH patients (31,32) and would increase voltage driven transport out 
of thick limbs and thence into the descending vasa recta and eventually the papillary 
capillaries and interstitium (13). Correlation of proximal delivery with direct measurements 
of interstitial calcium could test this model.
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So long as the papillary epithelium remains intact plaque is protected from the urine but 
once breached urine appears to create nucleations that form the base of an overgrowth 
(Figure 4, cartoons 3 to 8). What factors might lead to disruption of the urothelial barrier? Is 
it normal turnover unluckily over plaque? Does plaque somehow disturb the papillary 
epithelium? Gene and protein expression studies of papillary epithelium over plaque might 
or not might disclose clues to the process. The urine proteins that form the immediate 
overlay include THP and osteopontin (27), but the entire suite of proteins remains to be 
discovered. Are all urine proteins in their native concentrations or are some selected? Which 
ones? Are these the same in a group of patients or different between patients? Proteomic 
approaches seem ideal using biopsy materials.
We are aware of proteomic studies of materials eluted from kidney stones (40–47). These 
are of value in themselves. But being of the bulk phase of the stones they cannot give 
information about the initial nucleating sites over exposed plaque, which is the critical 
beginning of an attached stone. For that we must have biopsy materials and micro-
techniques.
Successive waves of nucleation and matrix may represent the same proteins or a changing 
array of proteins from urine; this latter is very important because perhaps changes of matrix 
are what permit conversion from HA to CaOx that makes up the bulk of the stones. The HA 
nucleation is unexplored; needed are studies of the proper urine protein ensembles exposed 
to solutions made up to resemble the ionic composition of urine. No doubt the matrix 
molecules control the nucleation and may vary from person to person. As for the particles 
themselves, why is the overlay layered? Does it reflect waves of SS? Is it some alteration of 
matrix composition? The specific composition of alternating layers, especially those with 
and without HA crystals should be accessible to modern proteomic and immuno-TEM 
approaches.
Most mysterious of all is eventual conversion of nucleation from HA to CaOx. Possibly the 
pH within the matrix changes as one moves away from the tissues. Possibly the matrix 
changes. This should be accessible not only from tissue biopsies but from stones whose 
layers include the early HA and later CaOx nuclei. Put perhaps most directly, why does 
CaOx have to appear at all? If the beginning of the stone is all HA, why can this beginning 
not merely progress to HA stones as a rule?
One might say that growth of HA/CaOx stones over plaque is so incompletely understood 
that many if not all of the researches we have mentioned are justified. WIth disclosure of the 
fine details later work can become refined and eventually this process understood at a 
molecular and atomic level. Nothing less will move this area of stone research forward. 
Human tissues should suffice so that the problems of experiment are not to create animal or 
cell models but to explore what is already produced in human kidneys.
Our group may have been relatively unique in obtaining human papillary biopsies but the 
techniques we used are commonplace in urological surgery and many research-oriented 
surgeons can obtain tissue. What we have done that is truly unique and probably necessary 
is demand as much strictness as possible in defining the clinical phenotype under study. We 
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have published evidence for much variability of tissue between clinical phenotypes, which 
must be controlled by selection of patients if chaos is to be avoided.
Although overgrowth on plaque occurs in people who produce brushite or HA stones 
(11,48), completely different phenotypes from ICSF, the process may not be the same in 
such patients as in ICSF. LIkewise overgrowth of CaOx on plaque occurs in patients with 
primary hyperparathyroidism, ileostomy, and small bowel resection (7–9). Patients with 
these systemic diseases do not have familial stones as do ICSF and idiopathic brushite and 
HA stone formers. Differences in plaque composition, matrix, and all other details of the 
process could be crucial for understanding this disease mechanism and the role of heredity, 
if any.
Bellini Duct plugging
Source of clinical stones
Although certainly not uncommon among stone formers, BD plugs have not as yet been 
proven as a source of clinical human stones. One might naturally assume that the open face 
of such plugs, bathed perpetually by urine and therefore exposed to CaOx and CaP SS of 
considerable magnitude (49,50), would foster nucleation of HA and CaOx thus producing an 
attached nascent stone that subsequently detaches and grows into a clinically important 
object. As attractive as this formulation might be, evidence for it is scanty at best.
BD plugs present to the surgeon as dilated BD filled with crystals (Figure 5 panel a). 
Sometimes crystals grow over the plugs into the urinary space (Figure 5 panels a and b). The 
rounded overgrowths on plugs from an HA and BR stone former respectively, are about 1–2 
mm (figure 6, images a-d). Imaginably such overgrowths could detach and grow within a 
calyx to reach 3 or more mm and present as passage of a stone.
The high resolution micro-CT images of the plugs (Figure 6, right hand series) show only 
HA for both the plug and overgrowth in the HA stone former (Figure 6, images a and b) and 
BR with a thin surface layer of CaOx for the overgrowth with a mixture of CaOx, BR, and 
HA for the base of the plug from the BR stone former (Figure 6, images c and d; Plug and 
overgrowth compositions are detailed in the legend to this figure and for all phenotypes in 
Table 1). It is therefore quite reasonable that HA and BR stones can originate on plugs, but 
even so proof is lacking at this point.
An obvious question is how one might know if a stone originated as the overgrowth over a 
BD plug. One possibility is that a stone attached to a papillum is found to be attached not on 
white plaque but to a BD plug. This would be evident to the surgeon and on intra-operative 
movies because as the stone was detached the area it grew on was not plaque but a dilated 
BD. Likewise the stone must have remnants of the plug at one border - where it was 
attached. We have not as yet observed removal of such a stone, but in fairness this has not 
been a specific surgical research aim.
Another possibility is that an overgrowth has detached and is free in the calyx or pelvis, 
grows into a clinically relevant stone and is removed. Within that stone one might predict 
the ghost remnant of the plug or overgrowth around which layers of new mineral have 
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created from a tiny overgrowth a larger stone. On study of our collection of stones we have 
found one example of such a ghost thus far (Figure 7). This renal pelvis stone from a patient 
with PHPT is 2 cm in length, 5 mm in width. On CT scanning a round inclusion was found 
(arrow and ring) which is HA and heterogeneous with respect to the rest of the stone. 
Possibly this was the original plug because its layers of HA are like those of plugs in being 
nodular vs the concentric rings of most stones as is seen here. Careful study of stones for 
heterogeneous inclusions may help clarify the question of whether BD plugs or overgrowths 
may be important stone nuclei.
Mechanisms for overgrowth on plugs
Overgrowth on plug surfaces is altogether unstudied even though Randall recognized the 
process (22). Like overgrowth on plaque, the only factors that seem available to control 
overgrowth on BD plugs must be the plug composition, urine SS values, and the urine 
molecules that deposit over plugs to create the matrix for overgrowth. The urine molecules 
that must cover the open face of BD plugs are unknown (13,14). Actual plugs with their 
overgrowths can be harvested and perhaps studied directly in their longitudinal dimension 
for matrix molecules and their relationship to crystals. Stones have been studied for their 
matrix (51,52) but not usually in an oriented manner like this one. Although we may be the 
first group to harvest BD plugs with their attached overgrowths, other surgeons can in 
principle do the same.
SS itself is not sufficient to explain the crystal composition of plugs and overgrowths. For 
example, both BR and HA stone formers have high urine CaP SS with respect to BR but the 
plugs of the former are composed of BR, CaOx and HA (Table 1) whereas those of the later 
are pure HA. Moreover, the overgrowth on plugs is BR in the former and HA in the latter 
(Table 1).
Papillary injury
Apart from stone genesis one significance of BD plugs is papillary injury from plugging. 
The injury plugs produce is obvious (Figure 5 panels e and f). The tubule epithelium can be 
completely destroyed so that crystals attach to the tubule basement membranes; dilation of 
BD may approach 20 fold normal. Around plugs the interstitium shows fibrosis, and 
hyaluronan expression - a mark of injury - occurs in epithelia of more modestly involved 
tubules and even of normal appearing tubules near plugged tubules (6,10). In some patients 
plugging extends into the IMCD; seen along their long axes through the papillary epithelium 
IMCD plugs appear as yellow cylinders, which we have called ‘yellow plaque’ (Figure 5 
panels c and d).
Cortical injury
Whereas ICSF cortices reveal virtually no pathology above that found in random people 
(Figure 8), cortices from HA and BR stone formers often show fibrosis, which could reflect 
procedures, such as SWL, or plugging. This question, the cause of the cortical injury, needs 
more study not so much with cutting edge bench techniques as with clinical research that 
attempts to dissociate cortical injury from the effects of treatments. Cortical injury occurs in 
all of the BD plugging states we have studied to date (1–11). But, of course, all of these 
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patients may have been exposed to treatments such as SWL and PERC which themselves 
injure the renal cortex (53–55).
Mechanisms for BD and IMCD plugging - animal and in vitro models
The process of BD and IMCD plugging has been studied in animals with oxalate 
nephropathy; crystal deposition in cortex has been studied in human transplant kidneys and 
phosphate nephropathy (56). Phosphate nephropathy and transplant crystals involve 
proximal and distal tubules, but papillary involvement is not documented because biopsies 
do not include that portion of the kidney (57). Whereas the IMCD and BD of animal oxalate 
loading models are filled with CaOx crystals (21,56,58–60), this is only seen in human PH1 
(10) and is not a model of ICSF or any other human stone disease, in which tubule crystals 
are mainly composed of HA.
What we have learned from renal cortex transplant crystals, cortical crystals in phosphate 
nephropathy, and from animal oxalate loading models is some idea about cell responses to 
crystals, and the cell injury mediators involved (56,61). But whether this knowledge 
translates into the BD plugging that occurs in common human stone diseases is unknown. 
For example, cortical renal cells may well respond to crystals in a manner far different from 
those lining the IMCD and BD. Likewise, CaOx crystals may well affect IMCD and BD 
cells differently from HA crystals, and rodent cells may respond differently from human 
cells. Moreover, phosphate nephropathy, transplant crystal deposition, and oxalate loading 
models in animals represent relatively acute crystal injuries compared to the much longer 
term evolution of a human disease that is known to occur over decades and is rarely 
associated with acute kidney injury with the exception of PH1.
Knockout mouse models are informative but likewise depart radically from human stone 
formers. SLC26a6 knockout mice develop hyperoxaluria, and in one knockout plugging 
occurs in proximal and distal tubules and stones are present in the renal pelvis (62). The 
other knockout with equivalent hyperoxaluria develops no crystal deposits or stones. 
NHERF knockout causes hypercalciuria and production of some papillary plaque and tubule 
plugging with HA in papillum (63). THP knockout produces plugging in the IMCD that 
gives way to plaque formation in the papillum (64). The latter two models have a potential 
to permit detailed studies of plaque, which have not as yet been exploited.
All of these models have immense potential to improve understanding of human stone 
formation and plugging but this cannot be realized until we have enough detailed knowledge 
of the human condition to link the animal and human findings together at a molecular and 
cellular level. Put another way if we do not know exactly what is happening in the human 
tissues at this level, how can we confidently interpret animal models?
Likewise for the many in vitro studies of crystal attachment to cell cultures derived from 
kidneys (65–68). In general these studies have established that crystals attach to cells at 
specific sites, cells respond to the crystals, may internalize them, and either break them 
down in their lysosomes or transport them to their basement membranes (56,61). However, 
the cells are not always relevant to BD and IMCD plugging, having been derived from 
proximal or distal cortical nephron which are certainly not the same as IMCD and BD cells 
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that have a different embryological origin. The crystals have often been CaOx whereas HA 
is more pertinent. The amounts of crystals, this being in vitro work, have often far exceeded 
what one might expect in a human BD or IMCD.
Mechanisms for BD and IMCD plugging - Human plug formation
The sequence of events that initiates human BD plugging is not well defined even though we 
have considerable information about the tissues after the process is established. An 
appealing idea derived from cell culture work is that SS drives crystallizations, and some 
kind of tubule cell injury exposes hyaluronan rich areas of the membrane to the tubule fluid 
so that crystals may anchor there (69). Evidence for this in humans has come from studies of 
transplant kidney crystals in cortex (70) but no human studies have shown it in papillum 
except our own in which hyaluronan expression was found in cortex and papillum in the 
absence and presence of crystals in patients with PH1 (10), and in the papillum of those with 
CaOx stones from obesity bypass (6). Hyaluronan expression was never found in papillae of 
ICSF even in regions of plaque. Other plug forming stone diseases have not as yet been 
studied in this detail.
The range of clinical stone phenotypes with BD plugs is very large. ICSF can have them 
(15) but their compositions is not as yet determined (Table 1). HA and BR stone formers 
always display plugging (Table 1, Figure 6 images a to d). Ileostomy, and primary 
hyperparathyroidism (Table 1, Figure 6, images e to h) each form complex plugs and 
overgrowths. Distal renal tubular acidosis, small bowel resection, obesity bypass, cystinuria, 
and PH1, are additional examples (1,3,5,9,10) in which plugging can be prominent, but we 
do not have examples of plugs and overgrowth to display.
Urine SS is easily measured and some progress has been made associating plug formation 
and CaP stone disease with higher urine pH (13), but SS values are not a sufficient 
explanation for the variety of crystals found in plugs and overgrowths. In ileostomy, plugs 
are urates and HA whereas urine pH hovers around 5 so that driving forces for urate salts 
and HA are absent (8). Small bowel resection causes HA plugs despite high CaOx SS and 
low CaP SS (9). It is true that SS values tend to associate with their predicted clinical stones 
- e.g. CaP SS with HA or BR stones (11) - but association with plugging is so poor in 
ileostomy and small bowel resection that other mechanisms must dominate the process. In 
dRTA, the paradigm of alkaline urine CaP stone formation (5) plugging is massive and 
mainly HA, but CaP SS is not as high as in BR stone formers who have much smaller 
numbers of plugs (Table 1). Pursuit of more basic understanding of plugging mechanisms in 
human tissues needs to go far beyond simple SS and crystallization.
IMCD stones
Thus far only observed in cystinuria these are unattached round tiny ‘stones’ within dilated 
IMCD () (Figure 9). Micro-liths of cystine about 1 to 2 mm in diameter are present at the 
distal ends of IMCD and are easily removed if the IMCD is unroofed with a laser (Figure 9, 
panels a and b). BD can be plugged with cystine, but without attachment of plugs within 
their tubules, so the plugs can be removed without force (3) and the epithelium remains 
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intact. This contrasts with all other BD plugs. Because they are round and unattached, 
formation in free solution is an obvious idea for cystinuria.
Free Solution formation apart from IMCD stones
At surgery one commonly finds myriads of unattached stones filling calyces and even the 
renal pelvis with no evidence on the stones of an attachment site. We refer here to the CaOx 
stones in PH1 and obesity bypass, most BR and HA stones, and all cystine stones (Figure 
10). In what ways is it possible even in principle to test and falsify the free solution 
hypothesis? To us this seems an ultimate challenge to the stone research community.
In the case of IMCD microliths, in cystinuria, stagnant urine is available as a breeding 
ground. But for the rest, the stones mentioned in the preceding paragraph, what would free 
solution formation mean? To us it would imply nucleation in urine, perhaps within a calyx, 
with some means for retention so that growth can occur. This theory is very close, in fact, to 
the plugging overlay hypothesis, in that the latter holds that tiny overlays are retained and 
grow. A commonly held speculation is that cell debris is shed from the renal pelvis and 
serves as an anchor and nucleation site (68).
Certainly crystals are forming in urine perhaps much of the time as all of us have found 
them during routine urinalysis. But none of us has ever observed these crystals becoming 
stones; all we have is the idea that somehow this may occur. The problem is that lacking a 
powerful means of experimental disproof this idea is not scientific but essentially 
metaphysical. For this reason, every effort is justified to work out new ways of testing 
mechanisms of clinical stone formation apart from growth on plaque and possibly as 
overgrowths on plugs.
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Figure 1. Attached stone to site of Randall’s plaque in ICSF patient
Panel a shows an endoscopic view of a calcium oxalate stone (arrow) attached to the tip of a 
papilla. Several sites of interstitial (Randall’s) plaque (arrowheads) are seen around the 
attached stone. Note the normal appearance of the papilla. Panel b shows the same papilla 
after the stone was removed. The papillary surface of that same stone is seen by light 
microscopy as an inset at the bottom left of this panel. A small site of whitish mineral 
(marked by asterisk) is clearly visible and was identified as hydroxyapatite while the rest of 
the stone is calcium oxalate. After performing micro-CT imaging of this stone, these images 
were aligned and superimposed onto the papilla in order to determine if the small site of 
hydroxyapatite aligned with a region of Randall’s plaque on the papilla. Indeed, the small 
apatite region on the stone aligned with a small bleed (see circled area) on a site of 
interstitial plaque, presumably the site where the stone was attached to the papillum.
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Figure 2. Histologic images showing initial sites of Randall’s plaque and its progression
Light microscopy reveals the initial sites of interstitial deposits (panel a, arrows) to be in the 
basement membranes of the thin loops of Henle at the papilla tip. By transmission electron 
microscopy, these sites of interstitial deposits are made up of numerous micro-spherulites of 
alternating lamina of matrix with and without crystals (panels b–e). The individual deposits 
are as small as 50 nm and grow into multi-layered spheres of alternating light and electron 
dense rings with the light regions representing crystals and the electron dense sites matrix 
material. Extensive accumulation of crystalline deposits occur around the loops of Henle 
(panel f, double arrows) spread into the nearby interstitial space extending to the urothelial 
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lining (panel g) of the urinary space. Disruption of the urothelial layer exposes the site of 
interstitial deposits to the urine which can trigger overgrowth of mineral and thus stone 
formation.
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Figure 3. Ultrastructural features of attachment site of kidney stone from idiopathic calcium 
oxalate stone former
Panel a is an endoscopic view of a half millimeter stone seen attached to papilla tip at a site 
of Randall’s plaque (arrow) while panel b shows the same stone by light microscopy with 
underlying tissue (arrow) after biopsy. Panel c shows the same stone-tissue complex seen in 
panel b but after demineralization. Note that the stone separated from the underlying tissue 
(rectangular box). Some tissue is still stuck to stone (asterisk) while the double arrowheads 
show a region of cellular debris. The single arrows point to areas on the papilla that still 
have a urothelial covering, these cells are lost at the stone-tissue junction. Panel d is a high 
magnification transmission electron micrograph of the tissue attachment site. The region of 
Randall’s plaque (lower right) is seen covered by a multi-layer, ribbon-like structure, have 
crystalline and matrix material, which are highlighted in the insert (upper right). A region 
marked “A” shows small (asterisk) and large crystals (single arrows) embedded in the outer 
(urine) side of the ribbon.
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Figure 4. Calcium oxalate stones grows on sites of interstitial (Randall’s) plaque
The earliest nuclei of plaque appear in the basement membrane of the thin loops of Henle 
(left most cartoon) as multi-layered spherulites of crystals and matrix material. 
Subsequently, interstitial plaque genesis (second cartoon, upper row) seems to occur on 
type 1 collagen in the interstitial space where individual spherulites appear to fuse. With 
time, islands of matrix and spherulites spread to the basal side of the urothelium and the 
plaque remains protected from the urine until the urothelium is breached (cartoon 3, upper 
row). At this point the urine appears to create nucleations that form the base of an 
overgrowth (cartoons 4 to 8). The urine proteins that form the immediate overlay include 
Tamm Horsfall protein (THP) and osteopontin (OP) followed by amorphous hydroxyapatite. 
As the overgrowth region expands there is a conversion of hydroxyapaittie to calcium 
oxalate (CaOx), the primary mineral of the stone of a ICSF stone patient.
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Figure 5. Endoscopic and histologic images from brushite stone formers
Papilla from BR patients (panel a) often showed depressions (arrows) near the papillary tip 
and flatting, a phenomenon not seen in the CaOx stone formers. Like CaOx patients, the 
papilla from brushite stone formers possessed sites of Randall’s plaque (arrowheads), 
though less in amount. In addition, the papilla possessed sites of yellowish crystalline 
deposit at the openings of ducts of Bellini (asterisk). These ducts were usually enlarged and 
occasional filled with a crystalline material that protruded from the duct that might serve as 
a site for stone attachment. Panel b shows crystal deposition in a papillary biopsy stained by 
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the Yasue method. Note crystal deposits in the lumens of individual inner medullary 
collecting ducts (arrows) and an occasional nearby loop of Henle. The crystal deposits have 
greatly expanded the lumen of these tubules and induced cell injury to complete cell 
necrosis in all of these same tubules. A cuff of interstitial inflammation and fibrosis 
accompanies sites of intra luminal disposition. Panel c shows a third (type 3) pattern of 
crystal deposits in papillary biopsies of brushite stone formers. Yellowish mineral deposition 
(single arrows) was found within lumens of medullary collecting ducts just like that 
described at the opening of ducts of Bellini, except that the type 3 deposits are located in 
collecting ducts just beneath the urothelium. Sites of type 3 deposits ranged from large areas 
of crystal deposition in collecting tubules that formed a spoke and wheel-like pattern around 
the circumference of the papilla to small, single sites of yellowish material in focal regions 
of a collecting duct lumen. Histologic analysis of the type 3 deposits (panel d) confirms that 
these sites of crystal deposition are in medullary collecting ducts (asterisk) positioned just 
beneath the urothelial lining (arrow). The double arrow shows a site of interstitial crystal 
deposition like that seen in idiopathic CaOx stone formers. Panel’s e and f were obtained 
from a papillary biopsy collected from a brushite patient here the gross morphology if all 
papilla was severely injured. Extensive regions of interstitial fibrosis surround the injured 
collecting ducts (double arrows). Entrapped injured thin loops of Henle and vasa recta (*) 
are noted in these fields of interstitial fibrosis. A series of crystalline-filled collecting tubules 
(arrow) are seen embedded in a small ring of fibrotic tissue. An occasional giant cell 
(arrowheads) was observed near damaged collecting ducts.
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Figure 6. High resolution micro-CT images of the BD plugs with overgrowths
Panels a, c, e, and g show a light micrograph of a BD plug with overgrowth region from an 
apatite, brushite, Ileostomy, and primary hyperparathyroidism stone patient respectively. 
Panels b, d, f, and h show a corresponding micro-CT image generated from 3D image stacks 
rendered for surface view and then sized for internal view from each of the plug/overgrowth 
structure. A dotted line demarks the region of the plug from the overgrowth which would 
occur at the opening of the duct of Bellini. The mineral forming the plugs from apatite 
(panel a–b), and primary hyperparathyroid (panels g–h) is entirely apatite. The plug from the 
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brushite patient (panels c–d) is a mixture of brushite, apatite and CaOx while the plug from 
the ileostomy (panels e–f) is apatite and urates. The overgrowth regions from apatite and 
primary hyperthyroid patients are primarily concentric layers of apatite, entirely CaOx for 
ileostomy patients and a mixture of CaOx and and BR for BR patients.
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Figure 7. Pelvic stone that possibly started as an overgrowth on a BD plug
This figure shows a long (about 2 cm) and slender renal pelvic stone removed from a patient 
with primary hyperparathyroidism and viewed by light microscopy and micro-CT. By CT 
the stone is seen as composed of apatite with a round inclusion region (denoted by arrow 
and ring) at one side of the stone. Possibly this inclusion region was the original plug 
because its layers of HA are like those of plugs in being nodular vs the concentric rings of 
most stones as is seen here.
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Figure 8. Cortical Interstitial fibrosis, tubular atrophy and glomerulosclerorsis in brushite 
(black circles), apatite (open circles) and ICSF (black triangles)
Left panel. After scoring cortical biopsies from BR, apatite and ICSF stone formers for 
interstitial fibrosis, tubular atrophy and glomerular injury, the highest score for interstitial or 
tubular atrophy was plotted on the x-axis and glomerular injury on the y axis for each 
phenotype. Out of 30 cases plotted, only 2 ICSF had interstitial changes above a score of 1, 
and none had significant glomerular disease with a glomerular score above 1, while 4/11 
apatite and 12/25 BRSF had significant cortical injury. Right Panel’s a–c shows the range of 
interstitial (arrows), tubular and glomerular (G) changes seen by light microscopy in the 
apatite and brushite patients. Panel a shows the cortex of an apatite patient with mild 
interstitial fibrosis and tubular atrophy (score = 1) and no glomerulosclerorsis while panel b 
shows an apatite patient with moderate interstitial fibrosis, tubular atrophy and 
glomerulosclerorsis (score =2). Panel c shows the cortex of a brushite patient with severe 
interstitial fibrosis, tubular atrophy and glomerulosclerorsis (score =3).
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Figure 9. Endoscopic unroofing of an IMCD ductal stone in cystinuric stone former
Micro-liths of cystine are present at the distal ends of IMCD and are easily seen at the time 
of percutaneous nephrolithotomy to lie under the urothelium at a site marked by a dark 
shadow (arrow) on a dilated duct (panel a). When the IMCD is unroofed with a laser (panel 
b), an unattached, round tiny ‘stone’ is exposed (double arrow) within dilated IMCD at 
easily flows out of the IMCD lumen.
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Figure 10. Cystine stones may be example of kidney stones formed in ‘free solution’
While numerous unattached stones are seen at the time stone removal by percutaneous 
nephrolithotomy or ureteroscopy only the stones from cystinuric patients have consistent 
characteristics of a stone formed in ‘free solution’ (panel a). The cystine stones look like 
‘Easter eggs” in that they are completely smooth, oval in shape, have a homogenous yellow 
coloration and are freely floating in a renal calyx. They are easily grasped and removed 
(panel b).
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